4 mg semaglutide Flex-Dose mL Injectable 2.5 mg/mL Sem-P™ - Getz Pharma -

None of GHK-Cu, BPC-157, or TB-500 has an approved human indication, and the GLOW combination specifically has no clinical trial establishing safety or efficacy in humans

ODS, Office of Dietary Supplements, National Institutes of Health

23 A combination of these data with a meta-analysis 3 reviewing rosiglitazone use, which showed a 43% increase in the rate of myocardial infarction (p=0.003) and a 64% nonsignificant increased risk of CV death (p=0.006) in patients using the drug, ultimately compelled the FDA to take immediate action toward changing the standard requirements for documenting safety of new medications seeking approval for T2DM treatment

De Jonghe

This means they stimulate insulin release primarily in the presence of high blood glucose levels, minimizing the risk of blood sugar dropping too low under normal circumstances